ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Provided By GlobeNewswire
Last update: Mar 31, 2025
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease
Read more at globenewswire.com0.9865
+0.08 (+8.89%)
Find more stocks in the Stock Screener
PMN Latest News and Analysis
